Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Docetaxel||Taxotere||Docetaxel anhydrous|Docefrez||Antimicrotubule Agent 12||Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).|
|Epirubicin||Ellence||Chemotherapy - Anthracycline 11||Ellence (epirubicin) is an anthracycline, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Ellence (epirubicin) is FDA approved as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement for primary breast cancer (FDA.gov).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 11||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Her2-receptor negative breast cancer||sensitive||Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil||Phase III||Actionable||In a Phase III trial, treatment with the combination of Avastin (bevacizumab) and Taxotere (docetaxel), Adrucil (fluorouracil), Ellence (epirubicin), and Cytoxan (cyclophosphamide) (D-FEC) resulted in improved efficacy over D-FEC alone in ERBB2 (HER2)-negative breast cancer patients, with pathological complete response in breast and lymph nodes in 22% (87/388) of patients (PMID: 25975632).||25975632|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|